BRCA1 promoter methylation in peripheral blood cells and predisposition to breast cancer

سرطان الثدي المبكر ورم خبيث منتشر، وهو أحد أسباب الوفاة بين النساء الشابات في المملكة العربية السعودية. إلى جانب ذلك، أظهرت البيانات أن غالبية المرضي يتقدمون للعلاج في مراحل المرض المتقدمة. والكشف المبكر لهذا المرض لا ينقذ حياة المرضى فقط، ولكن يمكن أن يخفض من المال والوقت المطلوبين لعلاج وتمريض مرضى سرطان الثدي المتقدم. يسلط هذا الاستعراض الضوء على خطر الإصابة بسرطان الثدي لدى النساء ممن يحملن مروج الجين رقم ١ المثبط لسرطان الثدي المُمَثْيَل في خلايا دمائهن البيضاء، ويقترح إمكانية استخدام هذا التعديل في التخلق المتوالي كعلامة جزيئية قوية للكشف المبكر عن سرطان الثدي

Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters

Abstract Background Constitutive methylation of tumor suppressor genes are associated with increased cancer risk. However, to date, the question of epimutational transmission of these genes remains unresolved. Here, we studied the potential transmission of BRCA1 and MGMT promoter methylations in mother-newborn pairs. Methods A total of 1014 female subjects (cancer-free women, n = 268; delivering women, n = 295; newborn females, n = 302; breast cancer patients, n = 67; ovarian cancer patients, n = 82) were screened for methylation status in white blood cells (WBC) using methylation-specific PCR and bisulfite pyrosequencing assays. In addition, BRCA1 gene expression levels were analyzed by quantitative real-time PCR. Results We found similar methylation frequencies in newborn and adults for both BRCA1 (9.9 and 9.3%) and MGMT (12.3 and 13.1%). Of the 290 mother-newborn pairs analyzed for promoter methylation, 20 mothers were found to be positive for BRCA1 and 29 for MGMT. Four mother-newborn pairs were positive for methylated BRCA1 (20%) and nine pairs were positive for methylated MGMT (31%). Intriguingly, the delivering women had 26% lower BRCA1 and MGMT methylation frequencies than those of the cancer-free female subjects. BRCA1 was downregulated in both cancer-free woman carriers and breast cancer patients but not in newborn carriers. There was a statistically significant association between the MGMT promoter methylation and late-onset breast cancers. Conclusions Our study demonstrates that BRCA1and MGMT epimutations are present from the early life of the carriers. We show the transmission of BRCA1 and MGMT epimutations from mother to daughter. Our data also point at the possible demethylation of BRCA1and MGMT during pregnancy